超级碰在线-超级碰碰永久免费视频播放-超级碰碰碰免费视频播放-超级碰碰碰免费视频-亚洲国产99在线精品一区69堂-亚洲高清资源在线观看

北京科興生物Sinovac Biotech???
北京科興生物制品有限公司是由中維科生物技術有限公司、北京北大未名生物工程集團有限公司合資組建的生物高科技企業。公司于2001年在北京中關村高科技園區北大生物城注冊成立，注冊資本14121萬元人民幣。2003年9月北京科興在美國OTCBB上市，并于2004年底轉板美國證券交易所（AMEX），是中國第一家在美國上市的疫苗公司。
北京科興以“讓中國兒童使用國際品質的疫苗，讓世界兒童使用中國生產的疫苗”為目標，憑借先進的生產工藝、國際化的質量管理、安全有效的產品品質、完善的售前、售后服務以及應對新發傳染病的強有力的研發體系，將在生物醫藥領域中占據重要地位。
　2009年9月3日，由北京科興生物制品有限公司生產的甲型H1N1流感病毒裂解疫苗“盼爾來福．1”獲得國家食品藥品監督管理局頒發的藥品批準文號，批準疫苗投入使用。全球首支獲得藥品批準文號的甲型H1N1流感疫苗由此誕生。



Sinovac Biotech Ltd., a biopharmaceutical company, focuses on the research, development, manufacturing, and commercialization of vaccines that protect against human infectious diseases in China. Its portfolio of regulatory-approved products consists of vaccines against the hepatitis A, hepatitis B and influenza viruses. The company offers Healive, an inactivated hepatitis A vaccine; Bilive, a combination hepatitis A and B vaccine; Anflu, a split virus influenza vaccine; and Panflu, a vaccine against the H5N1 influenza virus. The company’s pipeline vaccine candidates in the pre-clinical and clinical development phases include human vaccines for Enterovirus 71, Japanese encephalitis virus, and rabies; a vaccine for the SARS virus, which completed Phase I clinical trial; animal rabies vaccine; and a split viron vaccine for the H5N1 influenza virus, which completed Phase II clinical trial. It markets and sells its vaccine products primarily through various provincial and municipal centers for disease control and prevention. Sinovac Biotech Ltd. was founded in 1999 and is headquartered in Beijing, the People’s Republic of China.